# US 11,577,094 B2 · Systems and methods of light therapy for sexual dysfunction > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,577,094 B2 - Document ID: US11577094B2 - Status: Granted - Kind: B2 - Application number: 16/500,775 - Filed: 2018-04-09 - Published: 2020-03-19 - Granted: 2023-02-14 - Earliest claimed: 2017-04-10 - Assignees: The General Hospital Corporation - Applicants: The General Hospital Corporation - Inventors: Paolo Cassano - Web page: https://patentgrep.com/patent/US11577094B2 ## CPC - A61N 5/0622: {Optical stimulation for exciting neural tissue} - A61M 21/02: for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia (for massage A61H; electrotherapy A61N, e.g. applying alternating or intermittent electric currents for producing anaesthesia A61N1/36021) - A61B 18/203: {applying laser energy to the outside of the body} - A61M 2021/0044: {by the sight sense} - A61M 2210/1491: Clitoris - A61M 2210/167: Penis - A61N 5/067: using laser light - A61N 2005/0651: {Diodes} - A61N 2005/0652: {Arrays of diodes} - A61N 2005/0659: {infrared} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) ## Abstract Systems and methods for treating sexual dysfunction using transcranial photobiomodulation (t-PBM) with near infrared light (NIR) are provided. In particular, a device configured for treating a disorder of a subject, the device can have a power source and a light source configured to receive power from the power source to cause the light source to emit near infrared light, wherein the near-infrared light has a wavelength of 600 nm to 1400 nm. The device has a processor and a housing configured to position the light source to deliver the near infrared light to a region of interest of the subject via transcranial photobiomodulation in a dosimetry and duration sufficient to treat the disorder. ## Claims ### Claim 1 A device configured for treating a sexual dysfunction of a subject, the device comprising: a power source; a light source configured to receive power from the power source to cause the light source to emit near-infrared light; a processor; and a housing configured to position the light source to deliver the near-infrared light to a region of interest of the subject via transcranial photobiomodulation, the near-infrared light being in a dosimetry and duration sufficient to treat the sexual dysfunction of the subject, wherein the sexual dysfunction includes at least one of impaired libido, impaired sexual arousal, delayed orgasm, or absent orgasm, and wherein the near-infrared light is delivered at a wavelength of 830 nm at an average irradiance up to 36.2 mW/cm2 and a fluence over 30 min up to 65.2 J/cm2, with a treatment window of 28.7 cm2. ### Claim 2 (depends on 1) The device of claim 1, wherein the subject is depressed, and wherein the near-infrared light delivered to the subject is configured to treat the sexual dysfunction of the subject independently of treating the depression of the subject. ### Claim 3 (depends on 1) The device of claim 1, wherein the processor is configured to cause the light source to implement a duration of delivery of near infrared light of about 1 minute to about 120 minutes per day. ### Claim 4 A method of controlling a device configured for treating sexual dysfunction of a subject, the method comprising: providing power to a device having a light source to cause the light source to emit near-infrared light to a region of interest of the subject; and delivering the near-infrared light to a region of interest of the subject via transcranial photobiomodulation, the near-infrared light being in a dosimetry and duration sufficient to treat the sexual dysfunction, and wherein the sexual dysfunction includes at least one of impaired libido, impaired sexual arousal, delayed orgasm, or absent orgasm, and wherein the near-infrared light is delivered at a wavelength of 830 nm at an average irradiance up to 36.2 mW/cm2 and a fluence over 30 min up to 65.2 J/cm2, with a treatment window of 28.7 cm2. ### Claim 5 (depends on 4) The method of claim 4, wherein the duration of delivery of the near-infrared light is about 1 minute to about 120 minutes per day. ### Claim 6 A device configured for treating sexual dysfunction of a subject, the device comprising: a power source; a light source configured to receive power from the power source to cause the light source to emit near-infrared light, wherein the near-infrared light has a wavelength of about 830 nm; a processor; and a housing configured to position the light source to deliver the near-infrared light to a region of interest of the subject via transcranial photobiomodulation, the near-infrared light being in a dosimetry and duration sufficient to treat the sexual dysfunction, wherein the sexual dysfunction of the subject includes at least one of impaired libido, impaired sexual arousal, delayed orgasm, or absent orgasm, and wherein the near-infrared light is delivered at a wavelength of 830 nm at an average irradiance up to 36.2 mW/cm2 and a fluence over 30 min up to 65.2 J/cm2, with a treatment window of 28.7 cm2. ### Claim 7 (depends on 6) The device of claim 6, wherein the duration of delivery of the near-infrared light is about 1 minute to about 120 minutes per day. ### Claim 8 (depends on 1) The device of claim 1, wherein the sexual dysfunction of the subject is a first disorder of the subject, wherein the subject has a second disorder, and wherein the near-infrared light that is delivered to the subject via transcranial photobiomodulation is configured to cause a decrease in the severity of the sexual dysfunction, but not cause a decrease in the severity of the second disorder. ### Claim 9 (depends on 8) The device of claim 8, wherein the second disorder is depression. ### Claim 10 (depends on 6) The device of claim 6, wherein the transcranial photobiomodulation is administered bilaterally to the subject, and wherein the transcranial photobiomodulation is administered bilaterally to a forehead of the subject. ### Claim 11 (depends on 4) The method of claim 4, wherein the subject is depressed, and wherein the near-infrared light delivered to the subject via transcranial photobiomodulation is configured to treat the sexual dysfunction independently of the depression of the subject. ### Claim 12 (depends on 1) The device of claim 1, wherein the near-infrared light is configured to treat the sexual dysfunction of the subject, with the subject not being depressed. ### Claim 13 (depends on 4) The method of claim 4, wherein the subject is not depressed. ### Claim 14 (depends on 6) The device of claim 6, wherein the near-infrared light is configured to treat the sexual dysfunction of the subject, with the subject not being depressed. ### Claim 15 (depends on 1) The device of claim 1, wherein the transcranial photobiomodulation is administered bilaterally to the subject, and wherein the transcranial photobiomodulation is administered bilaterally to a forehead of the subject. ### Claim 16 (depends on 4) The device of claim 4, wherein the transcranial photobiomodulation is administered bilaterally to the subject, and wherein the transcranial photobiomodulation is administered bilaterally to a forehead of the subject.